Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CINGW CINGULATE INC C/WTS 03/12/2026 (TO PUR COM)
0.2000.0000.00%
Trading Session
01/31 09:30 ET
High
0.000
Open
0.000
Turnover
0.00
Low
0.000
Pre Close
0.200
Volume
0.00
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
Cingulate Benzinga All Live Access Appearance Rescheduled for December 16
KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology
Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
Consolidated Balance Sheet Data Consolidated Balance Sheet Data Consolidated Statement of Operations Consolidated Statement of OperationsPhase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in D
Cingulate Announces Agreement With Societal CDMO and Provides Clinical Update
New Partnership will Improve and Advance CING Manufacturing OperationsKANSAS CITY, Kan., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its pr
Cingulate to Present at LD Micro Investor Conference
KANSAS CITY, Kan., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform techn
Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103
Data Demonstrated Ability of CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone – Setting the Stage for Future Trials Employing Cingulate's Precision Timed Release™ (PTR™) Technol
Cingulate to Participate in Benzinga All Live Access Event
KANSAS CITY, Kan., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipelin
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
Globe Newswire 11-Aug-2022 6:45 AM$5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING),
Kansas City Business Journal Names Cingulate's Louis G. Van Horn a 2022 Chief Financial Officer of the Year
KANSAS CITY, Kan., July 25, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipelin
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders
KANSAS CITY, Kan., June 23, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipelin
Company Overview
More
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.
CEO： Dr. Shane J. Schaffer, Pharm.D.
Market： NASDAQ
Listing Date： 12/08/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet